It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Whole lung engineering and the transplantation of its products is an ambitious goal and ultimately a viable solution for alleviating the donor-shortage crisis for lung transplants. There are several limitations currently impeding progress in the field with a major obstacle being efficient revascularization of decellularized scaffolds, which requires an extremely large number of cells when using larger pre-clinical animal models. Here, we developed a simple but effective experimental pulmonary bioengineering platform by utilizing the lung as a scaffold. Revascularization of pulmonary vasculature using human umbilical cord vein endothelial cells was feasible using a novel in-house developed perfusion-based bioreactor. The endothelial lumens formed in the peripheral alveolar area were confirmed using a transmission electron microscope. The quality of engineered lung vasculature was evaluated using box-counting analysis of histological images. The engineered mouse lungs were successfully transplanted into the orthotopic thoracic cavity. The engineered vasculature in the lung scaffold showed blood perfusion after transplantation without significant hemorrhage. The mouse-based lung bioengineering system can be utilized as an efficient ex-vivo screening platform for lung tissue engineering.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tohoku University, Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
2 Tohoku University, Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); University Health Network, Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
3 Tohoku University, Institute of Fluid Science, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
4 University Health Network, Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Institute of Medical Science, Faculty of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
5 University Health Network, Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)